2022
Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
Waddell JT, Corbin WR, MacKinnon DP, Leeman RF, DeMartini KS, Fucito LM, Kranzler HR, O’Malley S. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. Alcohol Clinical And Experimental Research 2022, 46: 477-491. PMID: 35076087, PMCID: PMC9679805, DOI: 10.1111/acer.14780.Peer-Reviewed Original ResearchConceptsMedication dosageYoung adultsLight drinkingSubjective responsesSubjective effectsHeavy drinkingPlacebo-controlled studyEffect sizePerson effectsEffective treatmentNaltrexoneDrinking daysNaltrexone efficacySmall effect sizesDrinking levelsCravingDrinkingAdultsLaboratory-based studiesPillsMomentary assessmentEfficacyTreatment conditionsDrinking environmentsDaily diary data
2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants73936 Developing a Patient-Rated Outcome Measure of Alcohol and Drug Craving: A Systematic Review
Haeny A, Morean M, DeMartini K, Funaro M, O’Malley S. 73936 Developing a Patient-Rated Outcome Measure of Alcohol and Drug Craving: A Systematic Review. Journal Of Clinical And Translational Science 2021, 5: 39-39. PMCID: PMC8827664, DOI: 10.1017/cts.2021.505.Peer-Reviewed Original ResearchPatient-rated outcome measuresOutcome measuresSystematic reviewClinical trialsDrug useStimulant usePatient rated outcome measuresSubstance use disordersEffective treatmentPRISMA guidelinesUse disordersElectronic databasesDrug cravingPotential targetOpioidsCravingFDANicotineTrialsDisordersResults/CannabisReviewFindingsMedications